Acer Therapeutics Inc. financial data

Industry
Pharmaceutical Preparations
Location
One Gateway Center (300 Washington St.), Suite 356, Newton, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Opexa Therapeutics, Inc. (to 9/20/2017), PharmaFrontiers Corp. (to 6/2/2006), PHARMAFRONTIERS CORP (to 10/5/2005), SPORTAN UNITED INDUSTRIES INC (to 7/1/2004)
Latest financial report
10-Q - Q3 2023 - Nov 20, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 14.8 % -81%
Debt-to-equity -145 % +65.8%
Return On Equity 157 % -39.6%
Return On Assets -347 % -333%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 24.5M shares +49.4%
Common Stock, Shares, Outstanding 24.5M shares +49.4%
Entity Public Float 19.7M USD -43%
Common Stock, Value, Issued 2.45K USD +49.4%
Weighted Average Number of Shares Outstanding, Basic 24.5M shares +52.1%
Weighted Average Number of Shares Outstanding, Diluted 24.5M shares +52.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 372K USD
Cost of Revenue 83.8K USD
Research and Development Expense 8.03M USD -26.9%
General and Administrative Expense 10.6M USD -14.8%
Costs and Expenses 13.2M USD +153%
Operating Income (Loss) -27.4M USD -15.4%
Nonoperating Income (Expense) -21.1M USD -943%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -48.5M USD -128%
Earnings Per Share, Basic -2.24 USD/shares -93.5%
Earnings Per Share, Diluted -2.11 USD/shares -93.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 595K USD -90.7%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD
Inventory, Net 5.2M USD
Other Assets, Current 14.6K USD +169%
Assets, Current 6.14M USD -15.9%
Property, Plant and Equipment, Net 41K USD -55.7%
Operating Lease, Right-of-Use Asset 200K USD -33.3%
Goodwill 7.65M USD 0%
Other Assets, Noncurrent 173K USD -38.4%
Assets 14M USD -8.63%
Accounts Payable, Current 7.01M USD +49.5%
Employee-related Liabilities, Current 2.55M USD
Accrued Liabilities, Current 5.07M USD +31.3%
Liabilities, Current 61.7M USD +197%
Operating Lease, Liability, Noncurrent 76.7K USD -54.2%
Other Liabilities, Noncurrent 76.7K USD -54.2%
Liabilities 61.7M USD +124%
Retained Earnings (Accumulated Deficit) -180M USD -36.9%
Stockholders' Equity Attributable to Parent -47.7M USD -291%
Liabilities and Equity 14M USD -8.63%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.02M USD -199%
Net Cash Provided by (Used in) Financing Activities 13.1M USD +17.4%
Net Cash Provided by (Used in) Investing Activities -3.07K USD +89.4%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 24.5M shares +49.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 4.05M USD -49.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 595K USD -90.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 322K USD
Deferred Tax Assets, Valuation Allowance 55M USD +22.7%
Deferred Tax Assets, Gross 55.2M USD +22.7%
Operating Lease, Liability 183K USD -35.9%
Depreciation 15.5K USD -24.6%
Payments to Acquire Property, Plant, and Equipment 3.07K USD -89.4%
Lessee, Operating Lease, Liability, to be Paid 188K USD -38.7%
Property, Plant and Equipment, Gross 308K USD +0.16%
Operating Lease, Liability, Current 106K USD -10.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 107K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 26.4K USD -74.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.18K USD -75.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 54.6K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 17.5M USD +45.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Operating Lease, Payments 112K USD -50.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 122K USD +28.7%
Share-based Payment Arrangement, Expense 1.22M USD -36.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%